Top

Published in:

01-12-2013 | Clinical Guides in Oncology

SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013

Authors: J. García Gómez, M. E. Pérez López, M. Alonso Bermejo, Y. Escobar Álvarez, J. García Mata

Published in: Clinical and Translational Oncology | Issue 12/2013

Abstract

Chemotherapy-induced emesis (CIE) both in the form of nausea and vomiting is one of the adverse effects most feared by patients who receive treatment, and one of the factors that most affect their quality of life and limit their functional capacity for everyday activities. Chemotherapy-induced emesis can result from many factors, depending on the treatment and the patients themselves. The best treatment for CIE is prevention, based on the use of drugs aimed at inhibiting the signal of certain neurotransmitters involved in the process. Antiemetic prophylaxis for chemotherapy of high-emetogenous potential lasting 1 day includes a combination of anti-5-HT3, neurokinin-1 inhibitors and dexamethasone. Antiemetic prophylaxis for chemotherapy of moderate-emetogenous potential lasting 1 day includes a combination of palonosetron and dexamethasone. Prophylaxis is not recommended for chemotherapy with minimal emetogenous potential. In the case of unforeseen or refractory emesis the use of olanzapine, metoclopramide or phenothiazine should be considered.

Available only for authorised users

Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472–8.PubMedCrossRef

Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–94.PubMedCrossRef

Wilhelm SM, Dehoome-Smith ML, Kale-Pradhan PB. Prevention of postoperative nausea and vomiting. Ann Pharmacother. 2007;41(1):68–78.PubMedCrossRef

Noonan K. Effective prevention and management of chemotherapy-induced nausea and vomiting. Value-Based Cancer Care. 2012;3(suppl 2):12–4.

Navari RM. Management of chemotherapy-induced nausea and vomiting. Drugs. 2013;73(3):249–62.PubMedCrossRef

Hesketh PJ, Kris SM, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–9.PubMed

Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer. 2011;19(suppl 1):s43–7.PubMedCrossRef

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodriguez-Lescure A, Pastorelli D, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986–92.PubMedCrossRef

Aranda E, Constela M, Cortés-Funes H, Diaz-Rubio E, Gascón Villaplana P, Guillem Porta V, et al. Clinical Practice Guidelines on antiemetics in Oncology. Grupo de Trabajo sobre Antieméticos en Oncología. Sociedad Española de Oncología Médica. Expert Rev Anticancer Therapy. 2005;5(6):963–72.CrossRef

10.

Roila F, Hesketh PJ, Herrstedt J. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17(1):20–8.PubMed

11.

Grunberg SM, Hesketh PJ. Drug therapy: control of chemotherapy-induced emesis. N Engl J Med. 1993;329(24):1790.PubMedCrossRef

12.

Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18(2):163–73.PubMedCrossRef

13.

Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch JR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer. 2003;97(11):2880–6.PubMedCrossRef

14.

The Italian Group for Anti-emetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000;342(21):1554–9.CrossRef

15.

Geling O, Eichler H. Should 5-hydroxitriptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–94.PubMedCrossRef

16.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Antiemesis 1. 2013 updates.

17.

Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2001;9(5):350–4.PubMedCrossRef

18.

FDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran). http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm. Accessed 15 February 2013.

19.

Ondansetrón: Prolongación del intervalo QT del electrocardiograma y nuevas recomendaciones de uso. http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2012/NI-MUH_FV_14-2012.htm. Accessed 11 May 2013.

20.

Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;6841–3:1–7.CrossRef

21.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473–82.PubMedCrossRef

22.

Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single dose of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570–7.PubMedCrossRef

23.

Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, et al. A Phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9):1441–9.PubMedCrossRef

24.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10(2):115–24.PubMedCrossRef

25.

Botrel TEA, Clark OAC, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonina inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19(6):823–32.PubMedCrossRef

26.

Aogi K, Sakai H, Yoshizawa H, Masuda N, Katakami N, Yanagita Y, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer. 2012;20(7):1507–14.PubMedCrossRef

27.

Longo F, Mansueto G, Lapadula V, Stumbo L, Del Bene G, Adua D, et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract. 2012;66(8):753–7.PubMedCrossRef

28.

Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high dose cisplatin treatment. Ann Oncol. 2006;17(6):1000–6.PubMedCrossRef

29.

Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin. Analysis of combined data from two phase III randomized clinical trials. Cancer. 2005;104(4):864–8.PubMedCrossRef

30.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy ad tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822–30.PubMedCrossRef

31.

Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, et al. Efficacy ad tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Cancer. 2005;104(7):1548–55.PubMedCrossRef

32.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized double-blind study protocol-EASE. J Clin Oncol. 2011;29(11):1495–501.PubMedCrossRef

33.

Ioannidis JPA, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000;18(19):3409–22.PubMed

34.

Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy and tolerability analysis. Ann Oncol. 2007;18(2):233–40.PubMedCrossRef

35.

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189–98.PubMedCrossRef

36.

Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533–8.PubMedCrossRef

37.

Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188–95.PubMedCrossRef

38.

Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655–63.PubMedCrossRef

39.

Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus treatment. Support Care Cancer. 2011;19(Supl 1):1–4.CrossRef

40.

Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT, Bubalo U. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting n patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007;15(11):1293–300.PubMedCrossRef

41.

Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, double-blind, placebo-controlled, phase iii cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier oncology group study. J Clin Oncol. 2012;30(32):3998–4003.PubMedCrossRef

42.

Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliative Med. 2011;14(7):810–4.CrossRef

43.

Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM, Sancuso Study Group. on behalf of the Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double blind, phase III study. Support Care Cancer. 2011;19(10):1609–17.PubMedCrossRef

Title: SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013
Authors: J. García Gómez
M. E. Pérez López
M. Alonso Bermejo
Y. Escobar Álvarez
J. García Mata
Publication date: 01-12-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 12/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1093-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2013

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

SEOM Guidelines 2013: a response to the needs of Spanish oncologists

SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

Keynote webinar | Spotlight on antibody–drug conjugates in cancer